Hassan Aziz, MD was recognized in Physician's Weekly for his study on different survival outcomes for liver resection vs tumor ablation with multifocal hepatocellular carcinoma. physiciansweekly.com/in-multifocal-…

Mary Charlton, PhD, co-leader of the Cancer Epidemiology and Population Science Program is a previous awardee of the award. In the story, she shares how the award has benefitted her research and helped her become a more effective leader. now.uiowa.edu/news/2024/04/m…

ACCR Award: Jay (Zhijie) Li was awarded the Scholar in Training Award by the American Association of Cancer Research. This award is to recognize young investigators presenting. Jay wrote his on the influence of SUMOlyation on transcriptional regulation by ETV1 in Breast Cancer

A new clinical trial at Holden for adult-type granulosa cell tumors of the ovary.
clinicaltrials.uihealthcare.org/studies/nrg-gy…

A new clinical trial at Holden on the chemotherapy for relapsed patients of acute lymphoblastic leukemia.
clinicaltrials.uihealthcare.org/studies/aall21…

New Clinical trial at Holden on the dosage of medicine for patients with relapsed or refractory Acute Myeloid Leukemia.
clinicaltrials.uihealthcare.org/studies/phase-…

A new study on clear-cell renal cell carcinoma that came back or did not improve after treatment.
clinicaltrials.uihealthcare.org/studies/open-l…

New research trial for phase 2 study in patients who have progressed on immunotherapy and passed the pre-study test.
clinicaltrials.uihealthcare.org/studies/single…

New trial open for advanced solid tumors at Holden: clinicaltrials.uihealthcare.org/studies/phase-…

If you're at #AACR24 , be on the lookout for these selected abstracts from Holden researchers

Holden Researchers to Present New Cancer Research Data at 2024 AACR Annual Meeting | Holden AACR (uiowa.edu)

Join Dr. Yousef Zakharia at the virtual Targeted Oncology Case-Based Roundtable on Integrating New Approaches For Clear Cell RCC Into Practice.

Only 14 virtual participants, so secure your spot now!

Date & Time: March 27, 2024 | 6:30 pm – 8 pm CT

event.targetedonc.com/event/b5f86960…

Sarina Murray (Dupuy/Stipp) won an NIH/NMA Travel Award for 2023 NMA Annual Convention & Scientific Assembly and presented 'ABCB1 Promotes Uveal Melanoma Cell Resistance to FR900359 and Identifies a Tumor Cell Subpopulation with a Distinct Gene Expression Signature.' UI Holden Comprehensive Cancer Center

Congratulations to this year's O'Dorisio Award for NET Leadership #winner James Howe, MD from the University of Iowa. Thank you for your outstanding leadership in clinical treatment and research for NET!
#NeuroendocrineCancer #NeuroendocrineTumor #NETs #NCAN #CancerSupport #award

Today, we’re celebrating World Neuroendocrine Tumor (NET) Cancer Awareness Day – a day dedicated to bringing attention to this rare form of cancer. #NETCancerDay

Always motivating to hear patients successful stories, especially rare cancers.. Thanks Katie Coleman for sharing your story at #IKCSNA23 Kidney Cancer

University of Iowa Health Care was one of the higher accrual sites in the U.S. for this clinical trial, despite being in a less populated area. Dr. Mo attributes this to the UI's expertise in ophthalmology, particularly #uveal #melanoma . UI Holden Comprehensive Cancer Center NEJM #tebentafusp

Congratulations to Benjamin Miller for being named president of the Musculoskeletal Tumor Society.

Presented at #ESMO23 :

Tebentafusp is a bispecific molecule that recognizes CD3 and gp100. In a trial in patients with uveal melanoma, median survival at 3 years was 21.6 months with tebentafusp and 16.9 months with standard therapy.

Full IMCgp100-202 phase 3 trial results: